Status:
COMPLETED
Seric Calprotectine in Spondyloarthritis
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Spondylarthritis
Eligibility:
All Genders
18+ years
Brief Summary
To date, there are no biomarkers in spondyloarthritis that can differentiate between spondyloarthritis and fibromyalgia or other pathologies. Fecal calprotectin is a biomarker that is increasingly use...
Eligibility Criteria
Inclusion
- Patients in the active line of the rheumatology department with one of the following criteria:
- active spondyloarthritis (BASDAI \>4),
- or spondyloarthritis in low activity (BASDAI\<4),
- or fibromyalgia without associated inflammatory rheumatism,
- or healthy subjects (without inflammatory rheumatism and without fibromyalgia.
- Patients who have not objected to the use of their samples
Exclusion
- Minor patient
- Subject not affiliated to the social security system
- Subject deprived of liberty
- Patient under guardianship or curatorship
Key Trial Info
Start Date :
September 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 15 2018
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03818958
Start Date
September 15 2017
End Date
January 15 2018
Last Update
January 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nice Hospital
Nice, France, 06000